#United States #New York #The Gross Law Firm #MLTX #MoonLake Immunotherapeutics

Investors of MoonLake Immunotherapeutics Encouraged to Join Class Action for Recovery

In a recent announcement from The Gross Law Firm, shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) are urged to act quickly if they purchased shares during a specified class period. This call to action is aimed at those who have seen financial losses and want to seek recovery through a class action lawsuit. The firm emphasizes that appointment as a lead plaintiff is not necessary to participate in any recovery.

Background on the Class Period

The relevant class period for this action extends from March 10, 2024, to September 29, 2025. Investors during this timeframe might have been affected by allegedly misleading statements made by the company. Such statements are said to have falsely portrayed the efficacy and advantages of MLTX's sole drug candidate, SLK, compared to BIMZELX, a competing product. This led to a sense of unwarranted confidence in the stock, ultimately resulting in investor losses when the stock price dropped as the truth emerged.

Allegations Against MoonLake Immunotherapeutics

Key Points of Concern

The allegations indicate that during the class period, the defendants behind MLTX made several significant misrepresentations and omissions:
1. Misleading Drug Candidate Claims: Defendants allegedly stated that SLK and BIMZELX were fundamentally different due to their unique molecular targets on inflammatory cytokines IL-17A and IL-17F, which is contested.
2. Nanobody Structure Utility: It was claimed that SLK’s distinct nanobody structure would offer superior clinical benefits over traditional monoclonal structures like BIMZELX. However, according to the complaint, this assertion lacks scientific backing.
3. Efficacy Claims: Investors were led to believe that SLK's supposed enhanced tissue penetration would translate to actual clinical efficacy, a claim that is now under scrutiny.
4. No Basis for Optimism: Overall, the allegations suggest that the defendants did not have reasonable grounds for their lofty claims about SLK’s benefits, leading to investor reliance that resulted in financial losses.

Importance of Timely Action

For shareholders who believe they were affected, it is critical to act without delay. The deadline to register for participation in this class action is December 15, 2025. The Gross Law Firm provides an accessible online platform where affected investors can submit their information and enroll in a monitoring service that keeps them informed about the ongoing case.

Next Steps for Affected Shareholders

Once you register on the provided link, you will gain access to a portfolio monitoring service designed to keep you updated about the class action's progress. Importantly, your involvement in this case bears no monetary cost, making it a straightforward option for those looking to recover their losses.

Why Choose The Gross Law Firm?

The Gross Law Firm is a nationally recognized entity in the realm of class action law, known for its dedication to protecting investors' rights. The firm's mission encompasses advocating against deceit, fraud, and illegal business practices, ensuring all companies adhere to ethical standards. Their commitment to investor recovery and corporate responsibility sets them apart as a leading choice for class action representation.

Contact Information

For more detailed information or to register for the class action suit, you can contact The Gross Law Firm via:

• - Phone: (646) 453-8903
• - Email: [email protected]
• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018

In summary, if you are a shareholder of MoonLake Immunotherapeutics who has experienced losses during the specified class period, don't hesitate to reach out to The Gross Law Firm for guidance on participating in this important legal action.